Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
With a market cap of 1.35T, Eli Lilly(LLY) trades at $1,435.00. The stock has a price-to-earnings ratio of 47.42 and currently yields dividends of 0.46%.
During the trading session on 2026-11-16, Eli Lilly(LLY) shares reached a daily high of $1,475.25 and a low of $1,427.66. At a current price of $1,435.00, the stock is +0.5% higher than the low and still -2.7% under the high.
Trading volume for Eli Lilly(LLY) stock has reached 3.07M, versus its average volume of 3.23M.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,475.25 and a low of $850.51.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,475.25 and a low of $850.51.
LLY News
Eli Lilly (NYSE:LLY) agreed to acquire privately held Calytrix Bio in a deal valued at up to US$1.5b. The transaction brings Calytrix Bio's rare blood cancer p...
The past decade has been eventful for Eli Lilly (LLY +0.05%). The company made significant breakthroughs in diabetes and weight loss, which helped drive its mar...
Eli Lilly (LLY) is acquiring privately held Calytrix Bio in a deal that’s valued at up to $1.5 billion....
Analyst ratings
81%
of 32 ratingsMore LLY News
M&A Eli Lilly in up to $1.5B deal to acquire Calytrix Bio Nov 16, 2026, 1:16 PM ET Eli Lilly and Company (LLY) Stock JPM By : Jonathan Block, SA News Editor Eli...
Eli Lilly and Co. (NYSE:LLY) on Monday agreed to acquire Calytrix Bio Inc. for up to $1.5 billion in cash, as the drugmaker also presents new cardiometabolic da...
Calytrix Bio, a company developing precision, disease-modifying therapies for patients living with myeloproliferative neoplasms, announced a definitive agreemen...
Barclays analyst Emily Field raised the firm’s price target on Eli Lilly (LLY) to $1,550 from $1,400 and keeps an Overweight rating on the shares post the Q3 re...
Eli Lilly (LLY) and Company will present new data across its cardiometabolic health portfolio at ObesityWeek 2026, taking place November 14 to 17, 2026, in Wash...
Eli Lilly is leaning into its obesity and cardiometabolic franchise, reporting detailed Phase 3 results for Foundayo and Zepbound across conditions like obstruc...
Eli Lilly (NYSE:LLY) faces new lawsuits alleging its GLP-1 drug Mounjaro causes irreversible vision loss linked to NAION. Regulators in several countries issue...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.